臨床外科69巻1号

2014年01月発行

FOCUS

胃癌に対する二次治療の現況

著者： 小寺泰弘¹

所属機関： ¹名古屋大学大学院医学系研究科消化器外科学

ページ範囲：P.78 - P.82

文献概要

はじめに

　切除不能，転移性胃癌に対しては患者の状態が不良でなければ化学療法を行うのが標準治療である．その目的は現状では延命，症状の緩和である．近年では想定以上の効果がみられることもあり，長期にわたりcomplete responseが得られる場合や，転移巣が消失して原発巣の切除の提案に至る場合もある．しかし，多くの場合に治癒には至らない以上，患者および家族にとっては可能な限りの延命が望ましい一方で，限られた生存期間中の生活の質も重要である．

参考文献

1）Ajani JA, Moiseyenko VM, Tjunlandin S, et al：Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase Ⅲ trial for advanced gastric or gastroesophageal adenocarcinoma：the V-325 Study Group. J Clin Oncol 25：3210-3216, 2007

2）Ohtsu A, Shimada Y, Shirao K, et al：Randomized phase Ⅲ trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer：The Japan Clinical Oncology Group Study （JCOG9205）. J Clin Oncol 21：54-59, 2003

3）Boku N, Yamamoto S, Fukuda H, et al：Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer：a randomised phase 3 study. J Clin Oncol 10：1063-1069, 2009

4）Koizumi W, Narahara H, Hara T, et al：S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer （SPIRITS trial）：a phase Ⅲ trial. Lancet Oncol 9：215-221, 2008

5）Cunningham D, Starling N, Rao S, et al：Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358：36-46, 2008

6）Van Cutsem E, Moiseyenko VM, Tjulandin S, et al：Phase Ⅲ study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer：a report of the V325 Study Group. J Clin Oncol 24：4991-4997, 2006

7）Bang YJ, Van Cutsem E, Feyereislova A, et al：Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer（ToGA）：a phase 3, open-label, randomized controlled trial. Lancet 346：687-697, 2010

8）Kodera Y, Ito S, Mochizuki Y, et al：A phase Ⅱ study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer （CCOG0302 study）. Anticancer Res 27：2667-2671, 2007

9）Mochizuki Y, Ohashi N, Kojima H, et al：CPT-11 as a second-line treatment for patients with advanced/metastatic gastric cancer who failed S-1 （CCOG0702）. Cancer Chemother Pharmacol 2013, Epub ahead of print

10）Thuss-Patience PC, Kretzschmar A, Bichev D, et al：Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer. a randomized pahse Ⅲ study of the Arbeitsgemeinschaft Internistische Onkologie （AIO）. Eur J Cancer 47：2306-2314, 2011

11）Kang JH, Lee SI, Lim do H, et al：Salvage chemotherapy for pretreated gastric cancer：a randomized phase Ⅲ trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 30：1513-1518, 2012

12）Fujitani K, Narahara H, Takiuchi H, et al：Phase Ⅰ and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer. Oncology 69：414-420, 2005

13）Takiuchi H, Narahara H, Tsujinaka T, et al：Phase Ⅰ study of S-1 combined with irinotecan （CPT-11） in patients with advanced gastric cancer （OGSG0002）. Jpn J Clin Oncol 35：520-525, 2005

14）Wada Y, Yoshida K, Suzuki T, et al：Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines. Int J Cancer 119：783-791, 2006